Start here
Electrodesiccation and curettage is one of the most useful things a dermatologist does, and one of the easiest to use in the wrong place. On a small superficial basal cell carcinoma on the back or the shoulder it is quick, inexpensive, done in one visit, and the cure rate is very good. On the nose, on an eyelid, on a tumor with fuzzy borders, or on anything that has already come back once, it is the wrong choice.
What I find myself repeating is about the healing, not the cancer. There are no stitches. You leave with an open, shallow, weeping round wound that takes three to six weeks to close, and the scar it leaves is a flat pale circle, usually a little wider than the spot you came in about. People are ready for the cancer part and are not ready for that.
The other thing worth saying plainly is that nobody looks at the edges under a microscope. The scraping tells the doctor a great deal by feel, and it is not a margin check. That is the real trade for the speed and the low cost, and it is why the tumor has to be a low-risk one to start with.
— Dr. Schwarz, Board Certified Dermatologist
Key Facts
−
| Also called | Curettage and electrodesiccation, C&E, ED&C, curettage and cautery, "scrape and burn" |
| Downtime | No time off needed. The wound is left open and needs a daily dressing for 3 to 6 weeks |
| Sessions | One visit. The scrape-and-burn cycle is usually repeated two or three times within that visit |
| Typical cost | The least expensive of the surgical options. When it is done to treat a diagnosed skin cancer it is generally covered by US health insurance; a deductible or copay still applies |
| Results timeline | The cancer is treated that day. The wound closes in 3 to 6 weeks, and the scar keeps fading and softening for about a year |
| Pain | The numbing injection stings for under a minute. The procedure itself is not painful, and afterward the site is usually sore rather than painful |
| Cure rate | Commonly quoted around 95 percent at 5 years for carefully selected low-risk tumors. Substantially lower when it is used on tumors it was not meant for |
| Skin tone safety | The treatment works the same on every skin tone. The scar is what differs, and it is the main thing to plan around on deeper skin tones |
What It Is
−
Two instruments and one visit. After the area is numbed with a local anesthetic, the doctor uses a curette, a small instrument with a sharp spoon- or loop-shaped end, to scrape the tumor out. An electric needle or probe is then touched to the base, which chars a thin layer of tissue and stops the bleeding. That is the electrodesiccation. The pair is normally repeated two or three times in the same sitting. Nothing is stitched. The wound is left open and heals from the bottom up over several weeks. What it treats: Well-defined, low-risk skin cancers: superficial basal cell carcinoma, small nodular basal cell carcinoma on the trunk or limbs, and squamous cell carcinoma in situ, sometimes called Bowen's disease. It is also used for a number of harmless growths, including seborrheic keratoses, warts and pyogenic granulomas. It is not used for melanoma. It is also generally avoided for tumors on the central face, eyelids, ears, lips and nose, for aggressive microscopic subtypes such as infiltrative, micronodular and morpheaform basal cell carcinoma, for a cancer that has been treated once and returned, over hair-bearing skin, and anywhere the border cannot be seen clearly.
How It Works
−
The method relies on a difference in texture. Basal cell and squamous cell tumor tissue is soft and crumbly compared with the firm collagen of the normal dermis around and beneath it. A sharp curette drags through the soft tumor and catches at the firm normal tissue, so the doctor feels the edge of the growth rather than sees it. Scraping continues until the base and walls feel uniformly firm in every direction.
The electric current that follows does two jobs. It seals small vessels so the base stops bleeding, and it destroys a thin rim of tissue beyond where the curette reached, which acts as a margin of sorts. The char is then scraped away and the cycle repeated, because the second and third passes catch small nests of tumor the first one missed.
The wound is left open because closing it would hide the treated base. New tissue fills the crater from the floor upward while skin grows across from the rim, which is why the healed result is a flat round disc rather than a line.
What the method cannot do is confirm the cancer is gone. There is no intact specimen with edges for a pathologist to read. The judgment is the operator's fingers. That judgment holds up well on tumors that are shallow and clearly bordered, and poorly on tumors that are not, which is the whole reason the list of suitable tumors is narrow.
Skin is about two millimetres thick on the face. How deep a treatment reaches is most of what decides what it can and cannot change.
How deep Electrodesiccation and Curettage goes
This works around one to one and a half millimetres down, in the middle of the dermis where collagen is made. That is the depth that changes scarring and firmness, and it is also why the downtime is longer and the result takes months to appear.
See how it compares
This works around one to one and a half millimetres down, in the middle of the dermis where collagen is made. That is the depth that changes scarring and firmness, and it is also why the downtime is longer and the result takes months to appear.
This works in the epidermis, the top layer, only about a tenth of a millimetre thick. That is the right depth for surface pigment, flaking and rough texture, and it is why nothing at this depth can change a scar or a wrinkle that is set in the layer below.
This reaches just past the epidermis into the top of the dermis, around half a millimetre down. That is where fine texture, pores and the shallowest scarring sit. Deep enough to remodel a little, shallow enough that healing is measured in days.
This goes through the full thickness of the skin, past the collagen and down to where hair bulbs, larger vessels and glands sit. At this depth a treatment can reach structures creams never touch, and it is also where scarring becomes a real risk if it is done badly.
This works below the skin altogether, in the fat or the muscle beneath it. Nothing applied to the surface reaches here, which is the whole reason the procedure exists — and why it is done by injection, by needle or with a blade rather than with a cream.
Lost? See skin basics
The outer layer, and the only one anything in a jar reaches. It renews itself constantly: a cell made at the bottom takes about a month to reach the surface and flake off. Most of what a skincare product does, it does here.
The cells that make pigment. They sit along the base of the epidermis and hand melanin to the cells around them, which is what gives skin its color. Dark marks, melasma and the patch left behind by a spot are all these cells making more than usual.
A narrow tube running from the surface down into the skin, with an oil gland at the bottom of it. Oil travels up and out. When the tube blocks, what is behind it has nowhere to go — which is where blackheads and spots start.
Makes sebum, the oil that keeps the surface soft and stops water escaping. How much it makes is set by hormones, not by how often you wash — which is why scrubbing does not fix oily skin.
Cutibacterium acnes lives in the pores of everyone with skin. It is not an infection and it is not a hygiene problem. It only causes trouble when a pore blocks and it multiplies in the oil trapped behind it.
The scaffolding in the dermis that keeps skin firm and springy. It is built by fibroblasts and broken down by age, sun and smoking. Lines and looseness are collagen lost faster than it is replaced.
The living layer underneath, holding the blood vessels, the nerves and the collagen. It is where lasting change happens and it is hard to reach: most of what is sold for the skin never gets this far.
What It Treats
−




Not the Best For
−


Pros
−
- One visit, no stitches The cancer is treated on the day it is booked, and there is no return trip to have sutures removed.
- Least expensive surgical option No laboratory processing, no repair, few instruments. It is the cheapest way to treat a skin cancer surgically.
- Very good cure rate on the right tumor For a small, well-defined, low-risk basal cell carcinoma on the trunk or limbs, cure at 5 years is commonly quoted around 95 percent.
- No activity restriction There are no stitches to burst, so there is no two-week lifting restriction the way there is after an excision.
Cons
−
- No margin check Nothing goes to a pathologist, so nobody can confirm the edges were clear. Recurrence is found later, by watching.
- The scar is round and pale A flat, lighter disc, usually wider than the original spot, and permanent. On deeper skin tones the contrast is sharp.
- Weeks of open wound care Three to six weeks of daily cleaning and dressing, with weeping and crusting through much of it. Wounds on the lower leg heal slowest.
- A narrow list of suitable tumors Wrong for the high-risk zones of the face, for aggressive subtypes, for recurrent tumors, for hair-bearing skin, and for melanoma.
How to Prepare
−
What Happens
−
Recovery
−
Aftercare
−
Risks
−
Most of what happens after this procedure is expected rather than a complication: weeping, a yellow wound base, itching, and a scar you can see. Real problems are uncommon and worth recognizing early.
In Deeper Skin Tones
−
The procedure itself is not affected by skin tone. The tumor is scraped and the base is burned in exactly the same way, and the cure rate does not change. What differs is the mark it leaves.
The typical scar is a flat disc with less pigment than the skin around it, sometimes noticeably lighter. On deeper skin tones that contrast is much more visible, and it is usually permanent, because the pigment-producing cells in the treated base are destroyed along with the tumor. This is the most common regret after the procedure, and it is worth raising before booking rather than after.
Keloid and thickened raised scars are more common in people with deeper skin tones, and more likely again in anyone who has had one before. The highest-risk sites are the chest, shoulders, upper back and earlobes, which are also common places for these tumors. If you have ever had a keloid, say so. It can change which treatment is chosen, because an excision closed neatly under low tension sometimes scars better here, and it can mean treating the scar preventively with silicone or steroid injections rather than waiting to see.
Post-inflammatory hyperpigmentation, a brown or gray mark left where skin has been inflamed, is common in the first months and usually fades over six to twelve months. Daily sun protection over the site speeds that up. It is a different thing from the permanent pale scar and should not be mistaken for it.
One more point, and it is about diagnosis rather than treatment. Skin cancer is less common in people with deeper skin tones, and it is more often found at a later stage. It also turns up more often in places that see little sun: the palms, the soles, under a nail, and the mouth and genital skin. A new, changing, bleeding or non-healing spot in any of those places is worth showing to a doctor, whatever your skin tone. The gap in outcomes is about who gets examined, not about who can get skin cancer.
If You Stop
−
There is nothing to stop. This is a one-time treatment rather than something you keep having, so it does not fade or wear off the way an injectable or a peel does. Once the wound has healed, the treated tumor is either gone or it is not, and the scar is permanent.
Stopping the follow-up: That is the risk worth naming here. Two things are being watched for. The first is recurrence at the treated site, which is the specific weakness of a method with no margin check, and which usually appears within the first few years as a bump, a pearly rim, or a scab that keeps coming back at the scar edge. The second is a new cancer somewhere else. Having had one keratinocyte skin cancer makes another substantially more likely, and it is the more common of the two outcomes.
Stopping sun protection: This matters as well. It does not reactivate the treated tumor, but it drives new ones, and it makes a fresh scar pigment.
Stopping wound care early: This has a smaller but real cost. A wound allowed to dry out and crust heals more slowly and leaves a worse mark.
None of this produces a sudden change. The cost of stopping is that the next thing gets found later, when the treatment for it is larger.
Combining Treatments
−
Insurance Coverage
−
In the US it is billed as a destruction procedure, priced by the size of the lesion and the body site, and it is generally covered by health insurance when it is done to treat a diagnosed skin cancer. Your share is whatever your plan's deductible, copay and coinsurance come to. Coverage almost never applies when the same procedure is used to remove a harmless growth such as a seborrheic keratosis for appearance alone, which is billed as cosmetic.
The biopsy that diagnosed the cancer is billed separately, as is the pathology on it. Dressings and petrolatum are out of pocket and cost very little.
Prices without insurance vary widely by region, and by whether the office is hospital-affiliated. If you are paying yourself, ask for the specific procedure codes and a written estimate in advance. Offices can usually provide one.
Ask Your Doctor
−
At-Home Versions
−
How It Compares
−




Finding a Provider
+
This is done by dermatologists, and also by some primary care physicians, plastic surgeons, physician assistants and nurse practitioners working in dermatology. The instrument is simple. The skill is in choosing which tumors are suitable, and in feeling the difference between tumor and normal tissue.
Reasonable questions: what exactly the biopsy showed including the microscopic subtype, why this method rather than an excision or Mohs surgery, roughly how large the scar will be, and what the plan is if the cancer comes back.
Ask to see the pathology report: The report from your biopsy should name the tumor and, for basal cell carcinoma, the subtype. Superficial and nodular are the low-risk ones. Infiltrative, micronodular and morpheaform are not, and generally should not be treated this way.
Red flags: a growth treated this way without a biopsy first, no mention that the scar will be round and pale, an offer to do it on an eyelid margin or the tip of the nose without discussing Mohs surgery, and no arrangement made for a follow-up skin check.
Myths
+
- "Burning it off means the cancer is definitely gone." Nobody can say that with certainty after this procedure, because nothing is examined under a microscope. Cure rates are very good for well-chosen tumors, but "very likely gone" is the honest phrase, and it is exactly why follow-up checks are part of the treatment.
- "A yellow, weeping wound is infected." That yellow film is usually granulation tissue and normal wound fluid. Infection looks different: redness spreading outward, pain increasing after the first few days, thick or foul discharge, fever.
- "It should be scabbed over and kept dry." Old advice. Wounds left to dry and crust heal more slowly and scar more. Keep it covered and moist with plain petrolatum.
- "The scar will be smaller than the spot." It is usually a little larger, because the scrape extends past the visible edge and the burn extends past the scrape. It is round, flat, and lighter than the skin around it.
- "Skin cancer only appears on skin that gets sun." Most keratinocyte cancers are on sun-exposed skin, and not all of them are. Melanoma in particular can appear on the palms, soles, under nails, and on skin that is always covered. Location alone never rules it out.
- "People with deeper skin tones do not get skin cancer." Skin cancer is less common, not absent, and it is more often found at a later stage. That gap is about how often it is looked for.
Questions Patients Ask
+
Does it hurt?
The numbing injection stings for under a minute. After that you feel pressure and tugging rather than pain. Afterward the site is usually sore rather than painful, and plain acetaminophen is enough for most people.
Why don't they check the edges under a microscope?
Because there is no intact specimen to check. The tumor is scraped away in fragments and the base is burned. The method relies on the operator feeling the difference between soft tumor and firm normal tissue, which is reliable for shallow, clearly bordered tumors and unreliable for others. That trade-off is the reason it is limited to low-risk cancers, and the reason follow-up matters.
What will the scar look like?
A round, flat disc, usually slightly wider than the original spot and lighter than the skin around it. Some are a little sunken and some a little raised. It is pink or red at first and pales over about a year. It is permanent.
How long until it heals?
The open wound closes in about 3 to 6 weeks on the face, trunk and arms. On the lower leg it is slower, sometimes two to three months, particularly in older adults or with diabetes or poor circulation.
Can I have this instead of Mohs surgery on my face?
Sometimes, for a small superficial tumor on the cheek or forehead. It is generally not appropriate for the nose, eyelids, ears, lips, or the creases around them, where recurrence rates are higher and there is less spare skin. Ask specifically why one is being recommended over the other for your tumor.
What are the chances it comes back?
For a well-selected, small, low-risk tumor, cure at 5 years is commonly quoted around 95 percent. That figure falls when the method is used on tumors it was not meant for: aggressive subtypes, recurrent tumors, unclear borders, or high-risk facial sites.
References
+
- Garcia MS, Azari R, Eisen DB. Treatment of dermatosis papulosa nigra in 10 patients: a comparison trial of electrodesiccation, pulsed dye laser, and curettage. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 2010. — Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2010
- Sooksamran A, Pichai P, Suphannaphong M, et al. Previous therapy and the recurrence rate of basal cell carcinoma after Mohs surgery: a meta-analysis. Archives of dermatological research. 2023. — Archives of dermatological research, 2023
- Nguyen TH, Ho DQ. Nonmelanoma skin cancer. Current treatment options in oncology. 2002. — Current treatment options in oncology, 2002
- Tanese K. Diagnosis and Management of Basal Cell Carcinoma. Current treatment options in oncology. 2019. — Current treatment options in oncology, 2019
- Schwartz RA. The actinic keratosis. A perspective and update. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 1997. — Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 1997
